GENB

9.5408.00%
MG

Molly Gibson

Co-Founder

Ms. Molly Gibson, Ph.D, is Co-Founder of Generate Biomedicines, Inc. and served as a Chief Strategy and Innovation Officer at the firm. Ms. Gibson was Co-Founder of Lila Sciences and also served as it's Director from November 2025 until March 2026 and was it's President of Future Science until November2025. She serves as an Origination Partner at Flagship Pioneering, Inc working to found and grow companies at the intersection of AI and science. She also served as a Senior Principal at the firm since September 2019 and served as its Principal. She was a Senior Associate at Flagship Pioneering Inc since July 2018 until September 2019. She is working as part of a team of entrepreneurial scientists to conceive, create, resource and develop the next generation of Flagship’s first-in-category ventures. She joined Flagship in 2017 from Kaleido Biosciences and has expertise in computational biology and computer science to the Flagship team. At Kaleido, she played a key role in establishing a data science platform from the ground-up and successfully integrating robust quantitative learnings into all aspects of research. In this role, she created the first computational platform for drug discovery and a predictive understanding of pharmacological control of the human microbiome. She has also held engineering and consulting roles at Boeing and The BALSA Group. While at Washington University, she was a leader in science outreach and education. She served as Director and was on the board of the Young Scientist Program for three years, leading over 100 active volunteer scientists with the mission of bringing inquiry-based science to disadvantaged K-12 students. At the graduate level, she conceived and developed a bioinformatics course that is now standard for all incoming graduate students in biology and biomedical sciences. Her graduate research led to novel methods for studying the transmission of antibiotic resistance genes between the environment and clinical pathogens. She applied these methods to model the emergence of antibiotic resistance in the developing infant gut microbiome in response to specific durations and classes of antibiotic treatments. Her research was supported by several competitive fellowships, including a National Science Foundation Graduate Research Fellowship and she is co-author on multiple papers in top-tier journals. She received a Ph.D. in computational and systems biology from Washington University in Saint Louis from 2010 to 2015. She holds a B.S. in Computer Science from Truman State University in Missouri from 2005 to 2009.

Positions